SJ Medical
SJ Medical
The global coronary stent system market is undergoing a paradigm shift, driven by the increasing prevalence of cardiovascular diseases (CVDs) and a growing demand for minimally invasive surgical procedures. As of 2024, the industry is not just about "opening arteries"; it is about long-term vascular health, biocompatibility, and precision delivery. Manufacturers and suppliers are now focused on developing next-generation Drug-Eluting Stents (DES) and Bioresorbable Scaffolds (BRS) that minimize late-stage complications like stent thrombosis.
The aging global population and lifestyle-related health issues have surged the demand for Percutaneous Coronary Intervention (PCI). North America and Europe remain dominant markets, but the Asia-Pacific region is witnessing the fastest growth due to improving healthcare infrastructure.
Top-tier manufacturers must adhere to rigorous international standards including ISO 13485, CE marking, and FDA approvals. The complexity of manufacturing—involving laser micro-machining and pharmaceutical coating—requires high-capital investment and deep technical expertise.
Post-pandemic, global procurement strategies have shifted toward diversified sourcing. Hospitals and distributors are increasingly looking for reliable Chinese manufacturers who offer a balance of high-end technology and cost-efficiency.
Innovation in the coronary stent sector is moving toward "disappearing" implants and polymer-free delivery systems. As a leading supplier, we stay at the forefront of these technological milestones:
Unlike traditional metal stents that stay in the body forever, BRS are designed to provide temporary scaffolding and then dissolve once the vessel has healed. This restores the natural vasomotion of the artery.
To reduce the inflammatory response caused by permanent polymers, new stent systems utilize microporous surfaces to carry anti-proliferative drugs like Sirolimus directly on the metal strut.
Integration of stent sizing with AI-driven imaging (like OCT and IVUS) ensures perfect apposition and reduces the risk of procedural failure.
Hangzhou SJ Medical Co., Ltd. was established in 2015 and is dedicated to the research, development, manufacturing, and commercialization of vascular interventional medical devices. The company focuses on both cardiovascular and peripheral intervention fields, striving to provide safe, reliable, and innovative solutions for healthcare providers worldwide.
Over the years, SJ Medical has developed a comprehensive product portfolio covering key areas of vascular intervention. Its offerings span from various types of balloon catheters for coronary and peripheral applications to supporting access and diagnostic devices, as well as advanced stent systems. Through continuous innovation and strong R&D capabilities, the company has obtained multiple patents and international certifications, laying a solid foundation for sustainable growth in both domestic and global markets.
SJ Medical operates a modern manufacturing facility built in accordance with GMP standards. Our environment features a high-standard cleanroom, including a million-class clean workshop with localized hundred-class areas for critical processes such as drug coating and stent crimping.
Equipped with precision balloon forming equipment, laser welding, and high-precision laser cutting for Nitinol and Cobalt-Chromium alloys.
Our technical team consists of industry veterans with decades of experience in interventional cardiology and polymer science.
Strict adherence to ISO 13485 and CE protocols ensures every stent system meets the highest safety benchmarks for clinical use.
As a leading Chinese manufacturer, Hangzhou SJ Medical offers unique advantages for global distributors and hospital groups:
SJ Medical has established long-term partnerships with clients across Europe, Asia, the Middle East, and Africa. Its products are currently distributed in countries such as Finland, Italy, Spain, France, the Netherlands, India, Indonesia, Turkey, and Egypt, among others.
Our coronary stent systems are designed for a variety of complex clinical scenarios, ensuring that physicians have the right tools for every patient profile:
In emergency settings, the deliverability and rapid expansion of our PTCA balloon catheters and stents are critical for restoring blood flow quickly.
Our high-precision laser-cut stents offer the radial strength and flexibility required to treat complex vessel junctions without compromising side-branch access.
With ultra-low profiles, our Sirolimus-eluting systems are ideal for treating smaller coronary arteries where traditional stents might cause restenosis.
Our micro-guide wires and support catheters provide the torque control and pushability needed to cross the toughest calcified blockages.
SJ Medical strictly adheres to international quality standards and regulatory requirements. The company has obtained CE certification, ISO 13485 quality management system certification, and CFDA approval, along with free sale certificates, demonstrating its strong commitment to product quality and compliance.
Our services extend beyond manufacturing. We provide comprehensive and professional support throughout the entire customer journey. From pre-sales consultation and technical support to efficient order processing and responsive after-sales service, we ensure that every healthcare provider receives timely assistance and reliable solutions for their interventional needs.
Whether you are looking for a trusted OEM partner for laser-cut Nitinol stents or a reliable supplier for high-pressure PTCA balloon catheters, Hangzhou SJ Medical Co., Ltd. is your partner in advancing cardiovascular care.
